Ophthalmoplegia Market Research Report- Forecast Till 2027

Ophthalmoplegia Market Information: By Types (External Opthalmoplegia, Internuclear Opthalmoplegia), By Treatment (Surgery, Drug Treatment), By End Users (Hospital & Clinics, Ambulatory Clinics) - Forecast Till 2027

ID: MRFR/Pharma/2872-HCR | September 2022 | Region: Global | 80 Pages         

Ophthalmoplegia Market Speak to Analyst Request a Free Sample

Ophthalmoplegia Market Overview

Ophthalmoplegia Market is expected to grow at a CAGR 7.2% during the forecast year. Ophthalmoplegia is a condition in which the eye muscles are paralyzed or weak. It may affect one or more of the six muscles that stabilize and govern the movement of the eye. Ophthalmoplegia is a medical term that also refers to extra ocular muscular palsy. It is a syndrome in which the extra muscles of the eye that control eye movement are paralyzed. In this situation, the nerve fibers that govern both eyes in horizontal side-to-side movements are fragmented. The government's increased investment in research and development, as well as the growing elderly population, are projected to drive the ophthalmoplegia market's growth during the forecast period. The market is being driven by a growing aging population, rising healthcare knowledge and concerns, and other reasons. Additionally, the ongoing shift in global lifestyles is expected to fuel the expansion of the ophthalmoplegia market.

Additionally, rising healthcare costs are expected to restrain the growth of the ophthalmoplegia market. On the other hand, the increasing availability of low-cost replacements is expected to restrain the expansion of the ophthalmoplegia market over the forecast period.

Additionally, the advancement of technology and modernization of healthcare technologies will create additional prospects for the ophthalmoplegia market to flourish in the future years. However, rising treatment costs may provide a significant impediment to the ophthalmoplegia market's growth in the near future.

Figure: Global Ophthalmoplegia Market by Treatment Market Share, 2016 (%) Ophthalmoplegia Market


The global ophthalmoplegia market has been segmented on the basis of type, treatment and end user.

On the basis of types, the market is segmented into external ophthalmoplegia and internuclear ophthalmoplegia. External ophthalmoplegia is further segmented into superior recti, inferior recti, medial recti, lateral recti, inferior oblique, and superior oblique muscles.

On the basis of treatment, the market is segmented into surgery, drug treatment, and others. The surgery is further segmented into strabismus surgery and others.

On the basis of end users, the market is segmented into hospital & clinics, ambulatory clinics, and others.

Regional analysis 

The Americas dominates the global ophthalmoplegia market owing to well-developed technology and increased patient population with eye sight problem primarily due to increasing prevalence of diabetes. Additionally, high healthcare expenditure and the presence of some of the leading players have fuelled the growth of the market in this region.

Europe is the second largest ophthalmoplegia market, which is followed by Asia Pacific. Increasing government support and availability of funds for research drive the growth of the market. Asia Pacific is the fastest growing ophthalmoplegia market due to increasing geriatric population and rapidly developing medical sector.

On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities and poor economic and political conditions in Africa.

Key Players 

Some of key players profiled in the report are Abbott (US), Novartis AG (Switzerland), ZEISS International (Germany), Valeant Pharmaceuticals International, Inc. (US), Amritt, Inc. (US), Medline Industries, Inc. (US), ALLERGAN (Ireland), and Johnson & Johnson (US). 

Research Methodology Ophthalmoplegia Market-

The report for the global ophthalmoplegia market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Recent Development

March 2022: Abbott, the global leader in opthalmoplegia, announced that the latest version of its FreeStyle Libre continuous glucose monitor is now available to eligible persons with diabetes in the United Kingdom via the NHS. Abbott's wearable FreeStyle Libre 3 device – which the company bills as the world's smallest and thinnest real-time continuous glucose monitoring system – delivers glucose readings every minute directly to the user's smartphone for up to 14 days, allowing them to alter therapy as needed.

Intended Audience

  • Ophthalmic device manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities 

Report Scope:

Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2017-2023: 7.2%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott (US), Novartis AG (Switzerland), ZEISS International (Germany), Valeant Pharmaceuticals International, Inc. (US), Amritt, Inc. (US), Medline Industries, Inc. (US), ALLERGAN (Ireland), and Johnson & Johnson (US)
  Key Market Opportunities   Rapid developments in technology
  Key Market Drivers

  • Increasing number of people with ophthalmoplegia
  • Increasing geriatric population

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Ophtalmoplegia market is predicted to grow at a 7.2% CAGR between 2017-2023.

    The Americas is predicted to lead the ophtalmoplegia market.

    Major end users of the ophtalmoplegia market include ambulatory clinics, hospitals and clinics, and others.

    Key players profiled in the ophtalmoplegia market include Johnson & Johnson (US), ALLERGAN (Ireland), Medline Industries, Inc. (US), Amritt, Inc. (US), Valeant Pharmaceuticals International, Inc. (US), ZEISS International (Germany), Novartis AG (Switzerland), and Abbott (US).

    Availability of cheap alternative treatment and high treatment cost may limit the ophtalmoplegia market growth.